<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33139114</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3254</ISSN><JournalIssue CitedMedium="Internet"><Volume>210</Volume><PubDate><Year>2021</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>European journal of medicinal chemistry</Title><ISOAbbreviation>Eur J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-&#x4a1;B activators for the treatment of ALS.</ArticleTitle><Pagination><StartPage>112952</StartPage><MedlinePgn>112952</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2020.112952</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0223-5234(20)30924-7</ELocationID><Abstract><AbstractText>ALS is a rare type of progressive neurological disease with unknown etiology. It results in the gradual degeneration and death of motor neurons responsible for controlling the voluntary muscles. Identification of mutations in the superoxide dismutase (SOD) 1 gene has been the most significant finding in ALS research. SOD1 abnormalities have been associated with both familial as well as sporadic ALS cases. SOD2 is a highly inducible SOD that performs in concurrence with SOD1 to detoxify ROS. Induction of SOD2 can be obtained through activation of NF-&#x4a1;Bs. We previously reported that SRI-22819 increases NF-&#x4a1;B expression and activation in&#xa0;vitro, but it has poor ADME properties in general and has no oral bioavailability. Our initial studies were focused on direct modifications of SRI-22819. There were active compounds identified but no improvement in microsomal stability was observed. In this context, we focused on making more significant structural changes in the core of the molecule. Ataluren, an oxadiazole compound that promotes read-through and expression of dystrophin in patients with Duchenne muscular dystrophy, bears some structural similarity to SRI-22819. Thus, we synthesized a series of SRI-22819 and Ataluren (PTC124) hybrid compounds. Several compounds from this series exhibited improved activity, microsomal stability and lower calculated polar surface area (PSA). This manuscript describes the synthesis and biological evaluation of SRI-22819 analogs and its hybrid combination with Ataluren.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Bini</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA. Electronic address: bmathew@southernresearch.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA. Electronic address: pruiz@southernresearch.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Shilpa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA. Electronic address: sdutta@southernresearch.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Entrekin</LastName><ForeName>Jordan T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sixue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Kaval D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Micah S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augelli-Szafran</LastName><ForeName>Corinne E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA. Electronic address: caugelli-szafran@southernresearch.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowell</LastName><ForeName>Rita M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA. Electronic address: rcowell@southernresearch.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suto</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA. Electronic address: msuto@southernresearch.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Med Chem</MedlineTA><NlmUniqueID>0420510</NlmUniqueID><ISSNLinking>0223-5234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>K16AME9I3V</RegistryNumber><NameOfSubstance UI="C515878">ataluren</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Ataluren</Keyword><Keyword MajorTopicYN="N">NF-&#x4a1;B</Keyword><Keyword MajorTopicYN="N">Superoxide dismutase</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>3</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33139114</ArticleId><ArticleId IdType="doi">10.1016/j.ejmech.2020.112952</ArticleId><ArticleId IdType="pii">S0223-5234(20)30924-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>